Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Established and novel disease-modifying treatments in multiple sclerosis
A. H. Cross
,
R. T. Naismith
Department of Neurology
Institute of Clinical and Translational Sciences (ICTS)
Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
Section of Multiple Sclerosis & Neuroimmunology
Hope Center for Neurological Disorders
Research output
:
Contribution to journal
›
Review article
›
peer-review
121
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Established and novel disease-modifying treatments in multiple sclerosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Multiple Sclerosis
100%
Disease-modifying Therapy
100%
Novel Disease
100%
Natalizumab
50%
Autoimmune Disease
33%
Alemtuzumab
33%
Fingolimod
33%
Ofatumumab
16%
Initial Treatment
16%
Magnetic Resonance Imaging
16%
Central Nervous System
16%
Specific Mechanisms
16%
Monoclonal Antibody
16%
Safety Profile
16%
JC Virus
16%
Progressive multifocal Leukoencephalopathy
16%
Accurate Diagnosis
16%
Clinical Practice
16%
Therapeutic Agents
16%
Virus-neutralizing Antibody
16%
Safety Data
16%
Multiple Sclerosis Treatment
16%
Safety Monitoring
16%
Aggressive Disease
16%
Tolerability
16%
Mechanism of Action
16%
Neuronal Injury
16%
Clinical Benefit
16%
Axonal Injury
16%
CD52
16%
Risk-benefit Ratio
16%
Interferon-β (IFN-β)
16%
Immunomodulatory
16%
Efficacy Data
16%
Specific Marker
16%
Intolerance
16%
Possible Complications
16%
CD20
16%
Injectable Drugs
16%
Glatiramer Acetate
16%
Antibody-negative
16%
Oral Therapy
16%
Inflammatory Demyelination
16%
Individualized Treatment
16%
Ocrelizumab
16%
Suboptimal Response
16%
Postmarketing
16%
Dimethyl Fumarate
16%
Monitoring Strategy
16%
Switch Therapy
16%
Multiple Sclerosis Disease-modifying Therapies
16%
Teriflunomide
16%
New Criteria
16%
α4 Integrin
16%
Benefit Distribution Mechanism
16%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Diseases
100%
Natalizumab
37%
Autoimmune Disease
25%
Fingolimod
25%
Alemtuzumab
25%
Ofatumumab
12%
Immunosuppressive Agent
12%
Monoclonal Antibody
12%
Tolerability
12%
Demyelination
12%
Virus Antibody
12%
Beta Interferon
12%
Glatiramer
12%
Progressive Multifocal Leukoencephalopathy
12%
JC Virus
12%
Ocrelizumab
12%
Fumaric Acid Dimethyl Ester
12%
Teriflunomide
12%
Alpha4 Integrin
12%
Neuroscience
Multiple Sclerosis
100%
Natalizumab
42%
Autoimmune Disease
28%
Alemtuzumab
28%
Fingolimod
28%
Central Nervous System
14%
Monoclonal Antibody
14%
Immunosuppressive Drug
14%
JC Virus
14%
Progressive Multifocal Leukoencephalopathy
14%
Magnetic Resonance Imaging
14%
Beta Interferon
14%
Virus Antibody
14%
Glatiramer Acetate
14%
Diagnosis of Multiple Sclerosis
14%
Ocrelizumab
14%
Teriflunomide
14%
CD20
14%
Ofatumumab
14%
Alpha4 Integrin
14%
CD52
14%
Immunology and Microbiology
Multiple Sclerosis
100%
Natalizumab
42%
Autoimmune Disease
28%
Alemtuzumab
28%
Fingolimod
28%
Magnetic Resonance Imaging
14%
Monoclonal Antibody
14%
Immunosuppressive Drug
14%
JC Virus
14%
Virus Antibody
14%
Central Nervous System
14%
CD20
14%
Beta Interferon
14%
Ofatumumab
14%
Teriflunomide
14%
Glatiramer Acetate
14%
Fumaric Acid Dimethyl Ester
14%
Ocrelizumab
14%
Diagnosis of Multiple Sclerosis
14%
Alpha4 Integrin
14%